Ikena Oncology (NASDAQ: IKNA)
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-11-09 | ||||||
REV |
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.490 | -0.570 | -0.0800 | ||||
REV | 3.870M | 382.000K | -3.488M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Ikena Oncology (NASDAQ: IKNA) through any online brokerage.
Other companies in Ikena Oncology’s space includes: Xeris Biopharma Holdings (NASDAQ:XERS), Satsuma Pharmaceuticals (NASDAQ:STSA), Terns Pharma (NASDAQ:TERN), Marinus Pharma (NASDAQ:MRNS) and Incannex Healthcare (NASDAQ:IXHL).
The latest price target for Ikena Oncology (NASDAQ: IKNA) was reported by Credit Suisse on Friday, May 13, 2022. The analyst firm set a price target for 20.00 expecting IKNA to rise to within 12 months (a possible 281.68% upside). 3 analyst firms have reported ratings in the last year.
The stock price for Ikena Oncology (NASDAQ: IKNA) is $5.24 last updated August 15, 2022, 8:00 PM UTC.
There are no upcoming dividends for Ikena Oncology.
Ikena Oncology’s Q3 earnings are confirmed for Wednesday, November 9, 2022.
There is no upcoming split for Ikena Oncology.
Ikena Oncology is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.